Jeeni is an online entertainment service that aims to harness the growing reach of streamed music. It has close to 350 million subscribers and a growth rate of 39% Year-on-Year (YoY) providing billion-dollar revenues for digital disruptors. The Jeeni prototype was launched in April 2019. The company asserts that it offers artists an ethical revenue share. Five revenue streams are operating in parallel on the Jeeeni platform, namely, subscription-based memberships, online masterclasses, bespoke hardware sales, pay-to-view streamed events, and branded merchandise sales. The company's long term goal is to surpass its target paid subscriber numbers, achieve high subscriber growth and exit by acquisition. The investment raised will be used to further scale the company's capacity globally and build its mass artist showcases.
days to go:
Expired
investment:
£118,854
Rightangled is a DNA testing company backed by NHS that delivers services to consumers and medical/fitness specialists. The company is a full CQC healthcare provider license that has achieved registration with Bupa, a leading medical insurance company. The company is now planning to move into AI with a solid database. Rightangled has received excellent customer reviews with 5* on Google and 4.5* on Trustpilot. With the proceeds, the company will seek to launch its application, create a strong AI central system, and grow into new markets (US& UAE).
days to go:
Expired
investment:
£311,690
Secret Cinema (SC) is an entertainment company that creates immersive shows at venues across London, including interactive performances in purpose-built sets. The company has produced 50+ titles and sold one million tickets to date, with its biggest shows selling over 100,000 tickets each. SC was the brainchild of noted creative director Fabien Riggall who envisioned taking cinematic experiences to the next level. The company asserts that it has a Net Promoter Score (NPS) of 78. It held a screening of James Bond's 'Casino Royale' in Shanghai and has worked with Netflix to adapt its 'Stranger Things' show for a Los Angeles screening in 2020, reaching a US audience of over 300,000. The company will use the investment to support its growth, host its most popular slate of shows, collaborate on its first gaming title with a renowned gaming publisher, and sign a digital production with a major studio, based on a popular film franchise.
days to go:
Expired
investment:
£4,849,449
Accunea is the world’s first real-time continuous organ function monitoring company, specializing in biomarkers for kidney transplantation. Targeting NHS hospitals in the UK undertaking renal transplantation, the company aims to provide relief to patients awaiting organ transplants by ensuring availability of more organs for transplant and reducing the numbers of deaths due to increasing waiting list times. For this purpose, the company has designed a miniature analysis device which constantly monitors markers of kidney function and metabolism through a standard dribble line put into the vein of a patient. Accunea is raising £400,000 at a pre-money valuation of £2,230,000. The funds will be used to achieve clinical utility in Kidney and Pancreas.
days to go:
Expired
investment:
£388,038
DMD has made its digital content distribution enterprise in the last two years. Along with that, it has developed a global cinema TVOD (Transactional Video On Demand product). The company has built a long-term distribution partnership with OTT companies, telephone/IPTV and major cable that lead the wealthiest portion of the Pay TV market, providing service to 17 million two-way homes in 19 nations in Latin America. DMD's revenue has increased by 93% YoY 2017-2018, which will help the company in reaching EBITDA breakeven in Q3 of 2019. DMD has established relationships with distributors and leading sales agents in Europe and the USA. With the proceeds, the company will acquire bigger commercial films, increase its global footprint by launching the company in Asia, Africa, and Europe, and supplement its current output with classic titles.
days to go:
Expired
investment:
£145,000
Coras is a new technology ticketing platform connecting the world's tickets to people who wish to buy them for any event or activity. The portal has connected multiple ticketing systems into a single system opening up this market to new players for the first time. Coras's marketplace suppliers include West End Theatre tickets, Premier League football and tourist attractions. On the distribution side, it has partnered with Europe's largest airline, Ryanair, Frontier Airlines in the US and Tix.co in Australia. It has also signed other distribution partners in Europe & Asia which it'll announce soon. Ticketing is a $150 billion industry and Coras wants to be a strong contender in this segment. The company will use 85% of investment in software development and build the best product possible that can scale with its distribution and supplier partners.
days to go:
Expired
investment:
£625,760
EnXray are developing Low Energy X-ray (LEXR) technologies to sterilise equipment in commercial or research settings where low volume/high value therapeutic products, such as cancer vaccines and stem cell implants are being developed. Their aim is to reduce the need for third party providers and have the sterilisation process done on-site and on-demand with simple and safe equipment to reduce cost and save time for medical research organisations.
days to go:
Expired
investment:
£376,230
TC BioPharm is an immunotherapy company. It has used its patented technology to harness the power of a particular part of the immune system, Gamma Delta T-cells (GDT), to negate cancer cells in the human body. TC BioPharm has treated terminally ill patients with acute myeloid leukaemia in approved clinical trials garnering positive responses from multiple patients. The company has received regulatory approval from the Medicines and Healthcare products Regulatory Agency (MHRA) to run a COVID-19 clinical trial to address the global pandemic. TC BioPharm aims to use its current technology to provide a frozen product that can be manufactured cost-effectively and distributed globally. The company has already raised over £7 million in the last 15 months. It will use the investment to take its clinical trials forward in COVID-19 and cancer.
days to go:
Expired
investment:
£1,753,067
Trackd is a unique, award-winning music platform where artists create and audiences discover. With more than 261,000 users in 161 countries, this simple and intuitive application enables artists to record, collaborate, inspire, and share their ideas around the world. It has featured artists including Dave Stewart (Eurythmics), Valeras, and Blossoms. The app also features a ground-breaking social sharing tools “VirtualVinyl™” and allows video creation directly in the app. Trackd is exploring new and existing partnerships such as Rotor Video and Audio Technica as well as Apple for the next release. The company has already established a stellar team, built a 5-star app and have gained a huge amount of users in the past 3 years. The proceeds will be used for working capital, cash flow requirements, future upgrades, marketing, sponsorship, and events.
days to go:
Expired
investment:
£118,950
C-Major is a medical technology company. It asserts that over 2 million people suffer a Needle Stick Injury (NSI) every year and are at risk of contracting blood-borne viruses such as Hepatitis and HIV. It aspires to resolve this crisis by bringing to market its patented medical device, Controlled Helical Retraction Device, to prevent NSIs. The company argues that the device contains a ‘Helical Track’ mechanism for controlled acceleration of the needle during retraction as well as a ‘Sealed Port’ to minimise any blood splatter. C-Major endeavours to disrupt the $5.5 billion safety syringe market with its product. It is backed by the UK 'Innovation Seed' fund. C-Major will use the investment to complete the final design of its product for manufacture and assembly ahead of a Series A funding round in 2021.
days to go:
Expired
investment:
£211,595
